Prevention and Treatment of Lower Limb Deep Vein Thrombosis after Radiofrequency Catheter Ablation: Results of a Prospective active controlled Study
Clinical trial published in Scientific reports (2016)
Abstract
We conducted a prospective, single-center, active controlled study from July 2013 to January 2015, in Chinese patients with rapid ventricular arrhythmia who had received radiofrequency catheter ablation (RFCA) treatment to determine formation of lower extremity deep vein thrombosis (LDVT) post RFCA procedure, and evaluated the effect of rivaroxaban on LDVT. Patients with asymptomatic pulmonary thromboembolism who had not received any other anticoagulant and had received no more than 36 hours of treatment with unfractionated heparin were included. Post RFCA procedure, patients received either rivaroxaban (10 mg/d for 14 days beginning 2-3 hours post-operation; n = 86) or aspirin (100 mg/d for 3 months beginning 2-3 hours post-operation; n = 90). The primary outcome was a composite of LDVT occurrence, change in diameter of femoral veins, and safety outcomes that were analyzed based on major or minor bleeding events. In addition, blood flow velocity was determined. No complete occlusive thrombus or bleeding events were reported with either of the group. The lower incidence rate of non-occluded thrombus in rivaroxaban (5.8%) compared to the aspirin group (16.7%) indicates rivaroxaban may be administered post-RFCA to prevent and treat femoral venous thrombosis in a secure and effective way with a faster inset of action than standard aspirin therapy.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
We conducted a prospective, single-center, active controlled study from July 2013 to January 2015, in Chinese patients with rapid ventricular arrhythmia who had received radiofrequency catheter ablation (RFCA) treatment to determine formation of lower extremity deep vein thrombosis (LDVT) post RFCA procedure, and evaluated the effect of rivaroxaban on LDVT.
Warum dies für die Hirudotherapie relevant ist
Diese prospektive, aktiv kontrollierte Studie evaluierte die Wirksamkeit und Sicherheit von Rivaroxaban im Vergleich zu Aspirin zur Prävention tiefer Beinvenenthrombosen (TVT) bei 176 chinesischen Patienten nach Radiofrequenzkatheterablation. Die Studie ergab, dass Rivaroxaban im Vergleich zu Aspirin zu einer geringeren Inzidenz nicht-okklusiver Thromben führte, ohne dass vollständig okklusive Thromben oder Blutungskomplikationen auftraten. Es besteht keine direkte Relevanz für die American Society of Hirudotherapy, die Blutegeltherapie oder das Blutegel-Sekretom, da der Abstract weder Blutegel noch Hirudin oder andere aus Blutegeln stammende Verbindungen erwähnt. Die Forschung konzentriert sich ausschließlich auf den Vergleich pharmazeutischer Standardantikoagulanzien und Thrombozytenaggregationshemmer zur Behandlung postprozeduraler Venenthrombosen und liefert keine verwertbaren Daten für die Hirudotherapie-Forschung.
Zitation
Prevention and Treatment of Lower Limb Deep Vein Thrombosis after Radiofrequency Catheter Ablation: Results of a Prospective active controlled Study
Li L et al. · Scientific reports, 2016
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026